MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Corcept Therapeutics Inc

Fechado

SetorSaúde

83.9 -8.18

Visão Geral

Variação de preço das ações

24h

Atual

Mín

82.75

Máximo

91.64

Indicadores-chave

By Trading Economics

Rendimento

-16M

31M

Vendas

-656K

182M

P/E

Médio do Setor

92.862

63.778

EPS

0.26

Margem de lucro

16.904

Funcionários

500

EBITDA

-21M

26M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+45.76% upside

Dividendos

By Dow Jones

Próximos Ganhos

30 de abr. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

5B

12B

Abertura anterior

92.08

Fecho anterior

83.9

Sentimento de Notícias

By Acuity

28%

72%

83 / 386 Ranking em Healthcare

Corcept Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de abr. de 2025, 23:55 UTC

Ações em Alta

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 de abr. de 2025, 22:50 UTC

Grandes Movimentos do Mercado

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 de abr. de 2025, 21:08 UTC

Ganhos

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 de abr. de 2025, 21:00 UTC

Ganhos

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 de abr. de 2025, 23:56 UTC

Conversa de Mercado

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 de abr. de 2025, 23:44 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de abr. de 2025, 23:44 UTC

Conversa de Mercado

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 de abr. de 2025, 23:44 UTC

Principais Notícias

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 de abr. de 2025, 23:32 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 23:32 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 de abr. de 2025, 23:32 UTC

Conversa de Mercado

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 de abr. de 2025, 23:12 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de abr. de 2025, 23:12 UTC

Conversa de Mercado

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 de abr. de 2025, 23:10 UTC

Conversa de Mercado

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 de abr. de 2025, 23:09 UTC

Conversa de Mercado

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 de abr. de 2025, 23:09 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 22:57 UTC

Conversa de Mercado

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 de abr. de 2025, 22:56 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 22:56 UTC

Conversa de Mercado

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 de abr. de 2025, 22:43 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 de abr. de 2025, 22:12 UTC

Conversa de Mercado

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 de abr. de 2025, 21:48 UTC

Principais Notícias

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 de abr. de 2025, 21:41 UTC

Conversa de Mercado

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 de abr. de 2025, 21:17 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 21:17 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 de abr. de 2025, 21:17 UTC

Conversa de Mercado

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 de abr. de 2025, 21:04 UTC

Principais Notícias

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 de abr. de 2025, 21:03 UTC

Conversa de Mercado

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 de abr. de 2025, 20:53 UTC

Ganhos

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 de abr. de 2025, 20:52 UTC

Ganhos

Kaiser Aluminum Changes Inventory Acctg Methodology

Comparação entre Pares

Variação de preço

Corcept Therapeutics Inc Previsão

Preço-alvo

By TipRanks

45.76% parte superior

Previsão para 12 meses

Média 134 USD  45.76%

Máximo 150 USD

Mínimo 78 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Corcept Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

5

Comprar

0

Manter

0

Vender

Sentimento

By Acuity

83 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.